QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-initiates-coverage-on-milestone-pharmaceuticals-with-overweight-rating-announces-price-target-of-4

Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and ...

 milestone-pharmaceuticals-q2-eps-020-misses-017-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estim...

 why-is-milestone-pharmaceuticals-stock-plunging-on-friday

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support pot...

 milestone-pharma-prices-525m-equity-offering-with-warrants-offering-is-expected-to-close-on-or-about-july-14-2025

Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and...

 hc-wainwright--co-assumes-milestone-pharmaceuticals-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announc...

 milestone-pharmaceuticals-q1-eps-031-misses-018-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed the analyst consensus estim...

 hc-wainwright--co-maintains-buy-on-milestone-pharmaceuticals-lowers-price-target-to-10

HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

 why-is-milestone-pharmaceuticals-stock-plunging-today

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

 milestone-pharmaceuticals-says-fda-issued-complete-response-letter-regarding-its-new-drug-application-for-cardamyst-nasal-spray

The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manu...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION